Download CK Life Sciences Int`l., (Holdings), Inc.

CK Life Sciences Int'l., (Holdings), Inc.
Oncology  Neurology  Drug Development
DELEGATE(S)
Melvin Toh
2 Dai Fu Street, Tai Po Industrial Estate
NA Hong Kong
China
www.lsri.com.hk
Incorporated: 2001
Employees:
1300
Ownership:
Public
Stock Exchange of Hong Kong: 0775
MISSION/BACKGROUND
CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences") is focused on the research and
development ("R&D"), commercialisation, marketing and sale of products that improve the
quality of life by enhancing human health and the sustainability of the natural
environment. CK Life Sciences' product range is categorised into the areas of
pharmaceutical, nutraceutical and agricultural products.
CK Life Sciences' pharmaceutical R&D is focused primarily on oncology and diseases with
unmet needs. It is conducted at in-house laboratories, as well as in conjunction with
partner companies and academic institutions around the world.
The Life Sciences Research Institute carries out CK Life Sciences' pharmaceutical R&D initiatives. Headquartered in Hong Kong, the Life
Sciences Research Institute is committed to the R&D of cancer-related medicines, bringing new hope to cancer patients and their
families.
Listed on the Hong Kong Stock Exchange, CK Life Sciences is part of the Cheung Kong Group, a leading Hong Kong-based multinational
conglomerate.
Significant progress has been made, with two cancer-related products in advanced stages of clinical development in North America:
1) POL-103A, a therapeutic cancer vaccine, is being developed by Polynoma LLC, a subsidiary of CK Life Sciences in the US.
2) Tetrodotoxin, for pain management, is being developed by our subsidiary Wex Pharmaceuticals Inc.
TECHNOLOGY
1) POL-103A, a therapeutic cancer vaccine, is being developed by Polynoma LLC, a subsidiary of CK Life Sciences in the US.
2) Tetrodotoxin, for pain management, is being developed by our subsidiary Wex Pharmaceuticals Inc., listed on the Toronto Stock
Exchange.
Research is also ongoing in other focused areas, such as targeted cancer therapies, cancer immunotherapy and intranasal delivery
technologies.
ALLIANCES
The Life Sciences Research Institute is actively seeking partnership opportunities with academic institutions and biopharmaceutical
companies in order to grow its pharmaceutical pipeline. It is also exploring out-licensing possibilities and identifying potential partners
for co-development.
PRODUCTS
Name
Phase
Indication
Milestone
Tetrodotoxin
Phase III
Cancer-related Pain
Enrollment continuing
POL-103A Cancer
Immunotherapy
Phase III
Melanoma
Special Protocol Assessment (SPA) approved by FDA; new
Sponsor IND submitted December 2011
Tetrodotoxin
Phase II, IIa,
IIb
Chemotherapy-induced
Neuropathic Pain
Adaptive dose-ranging/proof-of-concept study starting
early 2012
POL-103A Cancer
Immunotherapy
Preclinical
NSCLC, Breast, Others
Preclinical Proof-of-Concept studies ongoing
Company Profiles – 24